Document is current
Any future updates will be listed below
-
Authors
Nauta, Ilse M.
Loughlin, Keeva N. M.
Gravesteijn, Arianne S. https://orcid.org/0000-0002-2458-2346
van Wegen, Jade
Hofman, Rosa P.
Wilmsen, Nathalie
Coles, Emma
van Kempen, Zoé L. E.
Killestein, Joep
van Oosten, Bob W.
Strijbis, Eva M. M.
Uitdehaag, Bernard M. J.
de Jong, Brigit A.
-
Funding
Funding for this research was provided by:
Dutch National MS Foundation (OZ2021-001)
- License Information
-
More Information
Article History
Received: 2 April 2025
Revised: 30 May 2025
Accepted: 2 June 2025
First Online: 24 June 2025
Declarations
:
: Ilse Nauta and Arianne Gravesteijn were supported by the Dutch National MS Foundation. Keeva Loughlin, Jade van Wegen, Rosa Hofman, and Zoé van Kempen have nothing to report. Bob van Oosten had received grants from Treatmeds and the Dutch MS Research Foundation, serves on data safety monitoring or advisory boards has royalties/licensees with Springer Media B.V. and is chair of the MS working group of the Netherlands Society of Neurology. Eva Strijbis has received research grants from ZonMW and the Dutch MS research foundation, and reports speaker relationships with Merck and Novartis. Nathalie Wilmsen and Emma Coles are employed by Voeding Leeft. Joep Killestein has received research grants for multicenter investigator initiated trials DOT-MS trial, ClinicalTrials.gov Identifier: NCT04260711 (ZonMW) and BLOOMS trial (ZonMW and Treatmeds), ClinicalTrials.gov Identifier: NCT05296161); received consulting fees for F. Hoffmann-La Roche Ltd, Biogen, Teva, Merck, Novartis, and Sanofi/Genzyme (all payments to institution); reports speaker relationships with F. Hoffmann-La Roche Ltd, Biogen, Immunic, Teva, Merck, Novartis, and Sanofi/Genzyme (all payments to institution); adjudication committee of MS clinical trials of Immunic (payments to institution only). Bernard Uitdehaag reports consultancy fees from Immunic Therapeutics. Brigit A. de Jong reported receiving grants from Dutch MS Research Foundation (project number 15-911), National MS Foundation, and Dutch MS Society. B.A. de Jong received research support from the Dutch National MS Foundation and the Dutch Ms Research foundation, she is member of the medical advisory board of the Dutch MS Society, chair of the committee for the revision of the guideline on disease-modifying therapy and MS for the Netherlands Society of Neurology, and chair of the committee of the Dutch National MS registration of the Netherlands Society of Neurology.
